Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)
Information source: Abbott
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Trandolapril (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Abbott Official(s) and/or principal investigator(s):
Global Medical Information 1-800-633-9110, Study Director, Affiliation: Abbott
Summary
The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor,
trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.
Clinical Details
Official title: A Prospective, Open-Label Study to Evaluate the Effect of an Escalating Dose Regimen of Trandolapril on Blood Pressure in Treatment-Naïve and Concurrently Treated Hypertensive Patients (TRAIL)
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Primary outcome: Effectiveness of escalating dose regimen of trandolapril in controlling blood pressure
Secondary outcome: Changes in blood pressure, safety.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Stage 1 or 2 Hypertension
Exclusion Criteria:
- Uncontrolled diabetes
- Subject has a hypersensitivity to ACE inhibitor
Locations and Contacts
Additional Information
Starting date: March 2004
Ending date: September 2005
Last updated: August 30, 2007
|
